These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36164623)

  • 21. Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by
    Li W; Kim TI; Kim JH; Chung HS
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31717574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.
    Brand Shwartz M; Assor M; Dotan N; Ratzon E; Cohen E; Ruimi N; Bloch I; Gal M; Yadid I
    Biochem Biophys Res Commun; 2018 Nov; 506(3):731-738. PubMed ID: 30384998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas.
    Porcellato I; Mecocci S; Brachelente C; Cappelli K; Armando F; Tognoloni A; Chiaradia E; Stefanetti V; Mechelli L; Pepe M; Gialletti R; Passeri B; Ghelardi A; Razzuoli E
    Animals (Basel); 2021 Jul; 11(7):. PubMed ID: 34359249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs.
    Derakhshani A; Asadzadeh Z; Safarpour H; Leone P; Shadbad MA; Heydari A; Baradaran B; Racanelli V
    J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refolding and characterization of recombinant human GST-PD-1 fusion protein expressed in Escherichia coli.
    Li DW; Yu JF; Chen YJ; Ma HB; Wang ZF; Zhu YB; Zhang XG
    Acta Biochim Biophys Sin (Shanghai); 2004 Feb; 36(2):141-6. PubMed ID: 14970911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
    Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
    J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
    Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide Blocking CTLA-4 and B7-1 Interaction.
    Podlesnykh SV; Abramova KE; Gordeeva A; Khlebnikov AI; Chapoval AI
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33419027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients: an impact on outcome.
    El Dein Mohameda AS; El-Rebey HS; AboElnasr LSA; Abdou AG
    Ecancermedicalscience; 2021; 15():1323. PubMed ID: 35047074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
    Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
    Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunoadjuvant effect of the extracellular domain of canine CTLA-4 on the VP2 protein of canine parvovirus].
    Wu Z; Sun H; Zhang X
    Wei Sheng Wu Xue Bao; 2008 Mar; 48(3):369-74. PubMed ID: 18479065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.
    Schlößer HA; Drebber U; Kloth M; Thelen M; Rothschild SI; Haase S; Garcia-Marquez M; Wennhold K; Berlth F; Urbanski A; Alakus H; Schauss A; Shimabukuro-Vornhagen A; Theurich S; Warnecke-Ebertz U; Stippel DL; Zippelius A; Büttner R; Hallek M; Hölscher AH; Zander T; Mönig SP; von Bergwelt-Baildon M
    Oncoimmunology; 2016 May; 5(5):e1100789. PubMed ID: 27467911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
    Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
    J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
    Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
    ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.
    Muto S; Inomata S; Yamaguchi H; Mine H; Takagi H; Ozaki Y; Watanabe M; Inoue T; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
    Anticancer Res; 2021 Dec; 41(12):6267-6272. PubMed ID: 34848482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.